Ondrej Fiala

Charles University

Czech Republic

Research Interests

Explore related searches

Professors in Immunology

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (5)

Radim Kubeš

University Hospital in Motol

CZECH REPUBLIC

View details

Federico Quaini

Adjunct Professor

University of Parma

ITALY

View details

Jakub Kucharz

Associate Professor

Centrum Onkologii-Instytut im Marii Skłodowskiej-Curie Warszawa

POLAND

View details

Milan Hora

head of department

Charles University, Faculty of Medicine in Pilsen

CZECH REPUBLIC

View details

Marco Stellato

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ondrej Fiala

Research Interests

Explore related searches

Contact this professor

Articles (10)

Non-coding transcriptome profiles in clear-cell renal cell carcinoma

First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study

Alpha-methyl CoA racemase (AMACR) reactivity across the spectrum of clear cell renal cell neoplasms

Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study)

Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetate

Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2(EV) Study

External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations

Giant Cell Temporal Arteritis Followed by Severe Encephalopathy Induced by Immunotherapy in a Patient with Metastatic Renal Cell Carcinoma Achieving Durable Partial Response: A Case Report

Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study

Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study

Collaborators (5)

Radim Kubeš

Federico Quaini

Jakub Kucharz

Milan Hora

Marco Stellato

Make your next move.